# Bristol Myers Squibb Shares Fall After Mixed Trial Results for Lung Disease Drug

- URL: https://stocks.freetheai.org/news/bristol-myers-squibb-shares-fall-after-mixed-trial-results-for-lung-disease-drug-3cbbf2
- Published: 2026-10-12T17:20:05Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NYSE:BMY](https://stocks.freetheai.org/symbols/NYSE-BMY)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Shares of Bristol-Myers Squibb Company (BMY) slipped 3.05% to $57.31 during Monday trading following mixed outcomes from a pivotal study evaluating admilparant, an oral medication for a severe lung condition. The trial achieved its main goal at a lower 60 mg twice-a-day dosage, demonstrating better lung function after 52 weeks compared to placebo. However, the higher 120 mg twice-a-day dosage did not achieve statistical significance in slowing lung function decline.

The findings highlight both promise and challenges for the drugmaker in treating idiopathic pulmonary fibrosis, a damaging organ illness with few effective remedies. On a positive note, the pharmaceutical firm also reported encouraging interim data from another late-stage study. Its radiopharmaceutical candidate RYZ101 successfully extended progression-free survival in patients with a rare form of neuroendocrine cancer who had already failed prior lutetium-based therapies.

Looking ahead, the enterprise plans to consult regulatory agencies regarding potential approval applications while preparing full dataset presentations for upcoming scientific conferences. Investors will also be tracking a separate Phase 3 study evaluating admilparant across a wider group of lung scarring patients, which is scheduled to release findings in early 2027.

## Key points

- Bristol-Myers Squibb stock fell 3.05% to $57.31 after posting mixed Phase 3 results for its oral lung drug admilparant.
- The 60 mg twice-daily dose met its primary goal for lung function at 52 weeks, but the 120 mg dose failed to show statistical significance.
- A separate trial for RYZ101 succeeded in patients with a rare neuroendocrine cancer, significantly prolonging progression-free survival.
- The company intends to confer with health regulators and anticipates data from another lung fibrosis study in early 2027.

## Questions and answers

### Why did Bristol Myers Squibb stock fall today?

Shares declined after late-stage trial data for admilparant showed that only the lower dose significantly improved lung function, while the higher dose failed to achieve statistical significance.

### What were the results of the admilparant IPF study?

The 60 mg twice-daily dose met its primary 52-week endpoint in measuring lung capacity improvement, but the 120 mg twice-daily dose did not reach statistical significance despite slowing function loss.

### Did Bristol Myers Squibb report any positive trial news?

Yes, an interim analysis for its cancer drug RYZ101 showed a statistically significant improvement in time without disease worsening for patients with rare neuroendocrine tumors.